Patents by Inventor Mark Epping-Jordan

Mark Epping-Jordan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8883826
    Abstract: The present invention relates to novel compounds of formula I wherein W, n, X and W? are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: November 11, 2014
    Assignee: Addex Pharma SA
    Inventors: Anne-Sophie Bessis, Christelle Bolea, Beatrice Bonnet, Mark Epping-Jordan, Nicolas Poirier, Sonia-Maria Poli, Jean-Philippe Rocher, Yves Thollon
  • Publication number: 20120277237
    Abstract: The present invention relates to novel compounds of formula I wherein W, n, X and W? are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Application
    Filed: December 20, 2011
    Publication date: November 1, 2012
    Applicant: Addex Pharma SA
    Inventors: Anne-Sophie Bessis, Christelle Bolea, Beatrice Bonnet, Mark Epping-Jordan, Nicolas Poirier, Sonia-Maria Poli, Jean-Philippe Rocher, Yves Thollon
  • Patent number: 8163775
    Abstract: The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: April 24, 2012
    Assignee: Addex Pharma SA
    Inventors: Anne-Sophie Bessis, Beatrice Bonnet, Emmanuel Le Poul, Jean-Philippe Rocher, Mark Epping-Jordan
  • Patent number: 8101637
    Abstract: The present invention relates to novel compounds of formula (I) wherein W, n, X and W? are defined in the description; invention compounds are modulators of metabotropic glutamate receptors-subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: January 24, 2012
    Assignee: Addex Pharma SA
    Inventors: Anne-Sophie Bessis, Christelle Bolea, Béatrice Bonnet, Mark Epping-Jordan, Nicholas Poirier, Sonia-Maria Poli, Jean-Philippe Rocher, Yves Thollon
  • Patent number: 8030331
    Abstract: The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: October 4, 2011
    Assignee: Addex Pharma SA
    Inventors: Anne-Sophie Bessis, Beatrice Bonnet, Emmanuel Le Poul, Jean-Philippe Rocher, Mark Epping-Jordan
  • Publication number: 20110112143
    Abstract: The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Application
    Filed: October 6, 2010
    Publication date: May 12, 2011
    Applicant: Addex Pharma SA
    Inventors: Anne-Sophie Bessis, Beatrice Bonnet, Emmanuel Le Poul, Jean-Philippe Rocher, Mark Epping-Jordan
  • Patent number: 7834035
    Abstract: The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: November 16, 2010
    Assignee: Addex Pharma SA
    Inventors: Anne-Sophie Bessis, Beatrice Bonnet, Emmanuel Le Poul, Jean-Philippe Rocher, Mark Epping-Jordan
  • Publication number: 20090124625
    Abstract: The present invention relates to novel compounds of formula (I) wherein W, n, X and W? are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Application
    Filed: June 17, 2005
    Publication date: May 14, 2009
    Applicant: Addex Pharmaceuticals SA
    Inventors: Anne-Sophie Bessis, Christelle Bolea, Beatrice Bonnet, Mark Epping-Jordan, Nicolas Poirier, Sonia-Maria Poli, Jean-Philippe Rocher, Yves Thollon
  • Publication number: 20070219187
    Abstract: The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Application
    Filed: November 4, 2004
    Publication date: September 20, 2007
    Inventors: Anne-Sophie Bessis, Beatrice Bonnet, Emmanuel Le Poul, Jean-Philippe Rocher, Mark Epping-Jordan